102.42MMarket Cap-0.77P/E (TTM)
0.819High0.680Low2.60MVolume0.704Open0.676Pre Close2.02MTurnover2.25%Turnover RatioLossP/E (Static)126.19MShares1.95052wk High-0.64P/B93.88MFloat Cap0.58152wk Low--Dividend TTM115.67MShs Float49.005Historical High--Div YieldTTM20.61%Amplitude0.581Historical Low0.774Avg Price1Lot Size
Karyopharm Therapeutics Stock Forum
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics (Nasdaq: KPTI)announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.
Phase 1 trial data showed pr...
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 Sentry Trial in Myelofibrosis
No comment yet